Dr. Steve Pakola is a licensed physician with over 20 years of biopharmaceutical experience, including over 15 years as a Chief Medical Officer for ophthalmology-focused companies. He has played leadership roles in preclinical and clinical development, regulatory affairs, and medical affairs. While Dr. Pakola's therapeutic area experience encompasses multiple indications, his predominant focus has been development of treatments for retinal disorders, including clinical development experience in diabetic retinopathy/diabetic macular edema and age-related macular degeneration. Dr. Pakola was the lead inventor and program leader for the Jetrea® (ocriplasmin) program since its inception in 2002 through to FDA and EMA marketing authorization submissions in 2012 (1st and only product approved for vitreomacular adhesion including macular hole in US, Europe, and rest-of-world).
MD - Chief Medical Officer